Tuesday September 26, 2017
PennyStockReporting.com

Hot Penny Stocks- PIP

A.J. Watkinson April 10, 2014 Hot Penny Stocks No Comments
Hot Penny Stocks- PIP

Scanning the PR newswires is just one of the ways I get trade ideas.  And sometimes, it’s a way to catch a hot penny stock that’s on the way down.  Hot for the wrong reason…

This week, I’ve picked up on a biotech stock that just hit a brick wall head on…

 PharmAthlene (PIP)

PharmAthene is a biodefense company developing medical countermeasures against biological and chemical threats in the US.   The company’s product candidates include SparVax, a protective antigen anthrax vaccine for post-exposure prophylaxis.  PIP also makes Valortim, a human monoclonal antibody to protect against and treat human inhalational anthrax and as a medical countermeasure for nerve agent poisoning.  The company serves the United States Department of Defense, Chemical Biological Medical Systems, Biomedical Advanced Research and Development Authority, the National Institute of Allergy and Infectious Diseases, and the National Institute of Health.

Financially, PIP has collaborated with Bristol-Myers Squibb for developing Valortim.  But unfortunately the company has run into a bit of a problem with their SparVax product…

Screenshot 2014-04-10 22.03.42Just this week, the company received notice from the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA).  The government agencies notified PIP of its decision to de-scope the current SparVax anthrax vaccine contract through a partial termination for convenience. BARDA will provide additional guidance to PharmAthene on the contractual changes, following which PharmAthene will evaluate its options for the SparVax program.

That’s not what a developmental drug company wants to announce… and the stock plummeted as a result.  The chart above shows the carnage- falling 28% over the past month alone!

Without the financial support of BARDA, the drug company will have to put this product on hold until another suitor can be found.  Just as with their Valortim product, PIP will need to pick up a big pharma partner like Bristol-Myers Squibb (or the government will need to step back up to the plate again).

But easier said then done.

————————————–

The Big 100% Winner-

When a drug company gets FDA approval, or passes from one clinical stage trial to another… the stock tends to pop as a result.  In fact, one of our premium stock picks that just received positive news from the FDA shot up 100% the very same day!  

If you’re curious to know which stock I picked, (read more here.)

—————————————-

In the end, PIP could still end up a good pharma investment- especially for a penny stock.    The company actually has $17.9 million in revenue, and also sports a very low 0.1x longterm debt-to-equity ratio… meaning they’re not dead in the water just yet.

Keep an eye on the news like I do, and you could end up catching a signal that PIP is a buy- but not just yet…

Keeping you one step ahead,

Signature

 

 

A.J. Watkinson

Summary
Article Name
Hot Penny Stocks- PIP
Author
Description
Bad news hits yet another micro-pharma and biotech company. Read more…

Like this Article? Share it!

About The Author

A.J cut his teeth while working for more than 12 years on the corporate side of the financial services industry in the suburbs of New York City. In addition, A.J. has successfully traded stocks, options and currencies as an independent trader since the late 90's. Eventually A.J. moved out of the "rat race", landing in North Scottsdale, Arizona. During the past few years, he's worked as the editor of a number of high profile financial newsletters. In this role, he's run trading services for penny stocks, options, currencies, ETFs, and FOREX. While under his direction, each of these trading services had turned in positive performance... something very rare in the financial newsletter industry. In addition, he's been a regular contributor to a number of financial websites- writing under multiple pen names. A.J.'s current goal is to share his real world experiences and success (and failures) in the various financial markets to help others not only make money- but avoid losing it. It's this vision and passion that has led A.J. to launch pennystockreporting.com. Most of all, A.J. hopes to keep the little guy from getting caught up in the highly unscrupulous penny stock pump and dump scene.

Leave A Response

You must be logged in to post a comment.